Biosceptre

Biosceptre

Biosceptre

Biosceptre takes a new approach to precision targeting of P2X7 in cancer, by exploiting a novel variant "non functional" P2X7 which has been shown to have a critical role in the survival of many cancer cell types.
Type
B2b
Raised
$15.5M
Follow us
Alexa global traffic share
Latest funding
£8,000,000
Venture capital (Series A) - 2017
Tuspark Science and Technology Service Group Bluesky Partnership II L.P
$4,692,720
Venture capital - 2014
Team Size
10+
Employees
Location
Headquarters

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when Biosceptre makes some noise.